Effect of bromelain on apoptotic and inflammatory pathways in cyclophosphamide-induced hepatotoxicity
Öz
Purpose: Cyclophosphamide (CP) has various adverse effects on the liver in both humans and animals. In the present study, the protective potential of bromelain (BRM), the main proteolytic enzyme derived from pineapple, was evaluated in a CP-induced hepatotoxicity rat model, with a focus on apoptosis and inflammation.
Materials and Methods: Twenty-four Wistar albino female rats were distributed to four equal groups (n = 6 per group): Control (received distilled water via oral gavage (o.g.) for 14 days), BRM (received 200 mg/kg BRM via o.g. for 14 days), CP (received 30 mg/kg/day CP intraperitoneally from day 8 until day 14 of the experiment), and CP+BRM. At the end of the study, immunohistochemical staining for caspase-3, tumor necrosis factor-alpha (TNF-α), toll-like receptor-4 (TLR-4), and nuclear factor-κB (NF-κB) was performed on kidney tissues from rats in all groups.
Results: In the microscopic evaluation, statistically significant increases in the immunoreactivities of caspase-3; 2.70 (1.80-2.70), TNF-α; 2.70 (1.80-2.70), TLR-4; 2.70 (1.80-2.70), and NF-κB; 1.80 (1.20-2.70) were observed in the CP group compared with the control group. However, in the CP + BRM group, BRM inhibited the CP-induced overexpression of apoptotic and inflammatory markers.
Conclusion: The present study provides new insights into the therapeutic potential of BRM against CP hepatotoxicity. BRM at dose 200 mg/kg has the capability to counteract the toxic effects of CP on liver tissue and has beneficial protective effects that is dose-dependent. BRM might represent a novel approach in the therapy of CP hepatotoxicity because of its anti-apoptotic and anti-inflammatory effects.
Anahtar Kelimeler
Cyclophosphamide, Bromelain, Liver, Inflammatory response, Caspase-3, TNF-α, TLR-4/NF-κB pathway
Kaynakça
- Zhong H, Lai Y, Zhang R, Daoud A, Feng Q, Zhou J et al. Low dose cyclophosphamide modulates tumor microenvironment by TGF-β signaling pathway. Int J Mol Sci. 2020;21:957.
- Heidari-Soreshjani S, Asadi-Samani M, Yang Q, Saeedi-Boroujeni A. Phytotherapy of nephrotoxicity-induced by cancer drugs: an updated review. J Nephropathol. 2017;6:254-63.
- Abdallah AN, Effat H, Mousbah AM, Ahmed HH, Abohashem RS. Cyclophosphamide: Potential hepatorenal toxicity and the possible therapeutic role of mesenchymal stem cell‐derived exosomes in wistar rats. J Biochem Mol Toxicol. 2026;40:e70705.
- Mahipal P, Pawar RS. Nephroprotective effect of Murraya koenigii on cyclophosphamide induced nephrotoxicity in rats. Asian Pac J Trop Med. 2017;10:808-12.
- Singh C, Prakash C, Tiwari KN, Mishra SK, Kumar V. Premna integrifolia ameliorates cyclophosphamide-induced hepatotoxicity by modulation of oxidative stress and apoptosis. Biomed Pharmacother. 2018;107:634-43.
- Van Den Boogaard, WMC, Komninos DSJ, Vermeij WP. Chemotherapy side-effects: not all DNA damage is equal. Cancers. 2022;14:627.
- Fouad A, Qutub H O, Al-Melhim WN. Punicalagin alleviates hepatotoxicity in rats challenged with cyclophosphamide. Environ Toxicol Pharmacol. 2016;45:158-62.
- Mahmoud AM, Germoush MO, Alotaibi MF, Hussein OE. Possible involvement of Nrf2 and PPARγ up-regulation in the protectiveeffect of umbelliferone against cyclophosphamide-induced hepatotoxicity. Biomed Pharmacother. 2017;86:297-306.
- Manzoor Z, Nawaz A, Mukhtar H, Haq I. Bromelain: Methods of extraction, purification and therapeutic applications. Braz Arch Biol Technol. 2016;59:e16150010.
- Chobotova K, Vernallis AB, Majid FAA. Bromelain'sactivity and potential as an anti-cancer agent: current evidenceand perspectives. Cancer Lett. 2010;290:148–56
